Cargando…

Wnt Signaling Pathway Pharmacogenetics in Non-Small Cell Lung Cancer

Wnt/β-catenin pathway alterations in non-small cell lung cancer (NSCLC) are associated with poor prognosis and resistance. In 598 stage III-IV NSCLC patients receiving platinum-based chemotherapy at MD Anderson Cancer Center (MDACC), we correlated survival with 441 host SNPs in 50 Wnt pathway genes....

Descripción completa

Detalles Bibliográficos
Autores principales:	Stewart, David J., Chang, David W., Ye, Yuanqing, Spitz, Margaret, Lu, Charles, Shu, Xiang, Wampfler, Jason A., Marks, Randolph S., Garces, Yolanda I, Yang, Ping, Wu, Xifeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237616/ https://www.ncbi.nlm.nih.gov/pubmed/24980784 http://dx.doi.org/10.1038/tpj.2014.21

Ejemplares similares

Inflammation-related Genetic Variations and Survival for Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy
por: Pu, Xia, et al.
Publicado: (2014)

Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer
por: Hildebrandt, Michelle A. T., et al.
Publicado: (2010)

Impact of self-reported physical activity and health promotion behaviors on lung cancer survivorship
por: Sloan, Jeff A., et al.
Publicado: (2016)

Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer
por: Zhao, Lina, et al.
Publicado: (2016)

A new scoring system for predicting survival in patients with non-small cell lung cancer
por: Schild, Steven E, et al.
Publicado: (2015)

Meta-Analysis on Pharmacogenetics of Platinum-Based Chemotherapy in Non Small Cell Lung Cancer (NSCLC) Patients
por: Yin, Ji-Ye, et al.
Publicado: (2012)

Pharmacogenetic testing in the Veterans Health Administration: Policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee
por: Vassy, Jason L., et al.
Publicado: (2018)

Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings
por: Maciel, Alejandra, et al.
Publicado: (2018)

Natural language processing for populating lung cancer clinical research data
por: Wang, Liwei, et al.
Publicado: (2019)

Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder
por: Groessl, Erik J., et al.
Publicado: (2018)

Predictive assessment in pharmacogenetics of Glutathione S-transferases genes on efficacy of platinum-based chemotherapy in non-small cell lung cancer patients
por: Ye, Huan, et al.
Publicado: (2017)

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility
por: Saldivar, Juan-Sebastian, et al.
Publicado: (2016)

Pharmacogenetics of Statin-Induced Myotoxicity
por: Kee, Ping Siu, et al.
Publicado: (2020)

Cancer pharmacogenetics
por: Marsh, S, et al.
Publicado: (2004)

Experimental Pharmacogenetics
por: Lubs, Herbert A.
Publicado: (1964)

Pharmacogenetics of Anticoagulants
por: Rane, Anders, et al.
Publicado: (2010)

Pharmacogenetics of osteoporosis
por: Marini, Francesca, et al.
Publicado: (2010)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

Pharmacogenetics of Antidepressants
por: Crisafulli, Concetta, et al.
Publicado: (2011)

Pharmacogenetics in the clinic
por: Guchelaar, H.-J.
Publicado: (2013)

Pharmacogenetics of Cannabinoids
por: Hryhorowicz, Szymon, et al.
Publicado: (2017)

Pharmacogenetics of thiopurines
por: Franca, Raffaella, et al.
Publicado: (2019)

Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer
por: Sissung, Tristan M., et al.
Publicado: (2019)

Genetic Variations in the Regulator of G-Protein Signaling Genes Are Associated with Survival in Late-Stage Non-Small Cell Lung Cancer
por: Dai, Jingyao, et al.
Publicado: (2011)

Method for Evaluating Multiple Mediators: Mediating Effects of Smoking and COPD on the Association between the CHRNA5-A3 Variant and Lung Cancer Risk
por: Wang, Jian, et al.
Publicado: (2012)

A Public Health Perspective on Preventing and Controlling the Spread of Coronavirus Disease 2019
por: Wu, Xifeng, et al.
Publicado: (2020)

How informative is a negative finding in a small pharmacogenetic study?
por: Bacanu, S-A, et al.
Publicado: (2012)

Pharmacogenetic Selection of Volunteers Increases Stringency of Bioequivalence Studies; The Case of Clopidogrel
por: Garcés-Eisele, J., et al.
Publicado: (2014)

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
por: Wagner, Alex H., et al.
Publicado: (2018)

Pharmacogenetics in the Brazilian Population
por: Suarez-Kurtz, Guilherme
Publicado: (2010)

Pharmacogenetics – Getting Closer
por: MacDonald, Ian M
Publicado: (2009)

Pharmacogenetics: The future medicine
por: Saini, Rajiv, et al.
Publicado: (2010)

Pharmacogenetics of asthma in children
por: Kondo, Naomi, et al.
Publicado: (2010)

Pharmacogenetics of lipid diseases
por: Ordovas, Jose M
Publicado: (2004)

Pharmacogenetics of analgesic drugs
por: Cregg, Roman, et al.
Publicado: (2013)

Pharmacogenetics of Antiplatelet Drugs
por: Curtin, Ronan, et al.
Publicado: (2002)

Pharmacogenetic research in Kazakhstan
por: Zholdybayeva, Elena, et al.
Publicado: (2014)

Pharmacogenetic And Tumour Drugs
por: Topic, Elizabeta
Publicado: (2005)

Application of pharmacogenetics in oncology
por: Miteva-Marcheva, Nelly N., et al.
Publicado: (2020)

MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non–Small Cell Lung Cancer
por: Li, Rong, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_per0t08j8p30p02jra0eq6sd94